Dr Piers Blombery speaks to ecancer at ASH 2018 about the resistance mechanism venetoclax in patients with progressive CLL.
He explains that venetoclex is an effective treatment for CLL however the majority of patients will relapse and it has been found that this is caused by the Gly101Val mutation of BCL2.
Dr Blombery notes that there are ways of tackling this mutation including using time-limited therapy as the mutation did not develop until 2 years of therapy.
Read more about this work here.
Watch his press conference here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.